{"id":"W4281786110","doi":"10.1200/jco.2022.40.16_suppl.9547","title":"Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i><sup>V600</sup> mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Vemurafenib; Interim analysis; Internal medicine; Melanoma; Gastroenterology; Oncology; Metastatic melanoma; Cancer; Confidence interval; Randomized controlled trial; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001648015,0.0008353422,0.001335863,0.0003205888,0.0001986577,0.0007092113,0.0005318779,0.000769054,0.003184104],"category_scores_gemma":[0.0008965603,0.0003283688,0.001827257,0.0002476006,0.0004631825,0.0007157305,0.000381047,0.001837893,0.0005380372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005964016,"about_ca_system_score_gemma":0.0007200722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003055312,"about_ca_topic_score_gemma":0.0007542432,"domain_scores_codex":[0.9996152,0.0001440323,0.0000286554,0.00008953367,0.00003852514,0.00008412578],"domain_scores_gemma":[0.9994986,0.0001032413,0.0001607866,0.00005257171,0.00002789457,0.0001569919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9099008,0.01122402,0.01177713,0.0004062024,0.001850388,0.00006944116,0.00008067409,0.001613867,0.0102873,0.0001414896,0.003020534,0.04962831],"study_design_scores_gemma":[0.2728827,0.6619965,0.05098925,0.00007083542,0.003077879,0.0002571406,0.00005212448,0.002078404,0.005550662,0.0002390796,0.002760712,0.00004477096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949639,0.001072268,0.0003349757,0.0001128607,0.00007695908,0.0004471808,0.001579962,0.00005380239,0.001358117],"genre_scores_gemma":[0.9945753,0.0004660246,0.0004489543,0.0002363906,0.00008391551,0.0007742749,0.002428716,0.00001210042,0.0009743965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003184104,"threshold_uncertainty_score":0.01065189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03743621221979902,"score_gpt":0.3705569719617181,"score_spread":0.333120759741919,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}